Joseph P. Hazelton

Executive Vice President, Chief Operating Officer

Joe Hazelton serves as Executive Vice President, Chief Operating Officer of Charleston Laboratories, Inc.  Mr. Hazelton joined Charleston Labs in 2014 to lead the company’s transition to the commercial stage of the novel fixed-dose combination pain product, CL-108.  In late 2016, Mr. Hazelton was elevated to Chief Operating Officer to further exploit his leadership and vast experience.  Prior to joining Charleston Laboratories, Mr. Hazelton spent over 15 years at Novartis Pharmaceuticals Corporation in advancing commercial roles in multiple disciplines and segments including his most recent position as a formal member of the US Managed Markets and Multiple Sclerosis Business Unit leadership teams, where he was responsible for leading the development and execution of the US Managed Markets & Market Access strategic plan for the MS Franchise, which includes the blockbuster product Gilenya®.  Mr. Hazelton’s previous roles at Novartis provided him broad knowledge in many different therapeutic areas and experience in key business segments such as managed markets/market access, retail and specialty pharmaceuticals, pricing, sales, and marketing.  Past responsibilities include the development and leadership of the Market Access functional team at Novartis, Director of Account Management for managed care/market access in the Midwest Region, and direct experience successfully leading sales teams in all aspects of product promotion and sales for multiple blockbuster medications such as Diovan® and Lamisil®.  Mr. Hazelton has extensive experience throughout his career working on all phases of the product lifecycle for many unique compounds including multiple fixed-dose combination products.  Mr. Hazelton received his BA from the College of the Holy Cross in Worcester, MA.